Dr. Hope Rugo
MD, FASCO
Division Chief, Breast Medical Oncology & Director, Women's Cancers Program
corporate_fareCity of Hope Comprehensive Cancer Center, Duarte, California
Hope Rugo
MD, FASCO
Dr. Hope S. Rugo is a physician-scientist and one of the most respected breast medical oncologists in the United States, with more than 35 years of experience in academic oncology and breast cancer care. She currently serves as Division Chief of Breast Medical Oncology and Director of the Women's Cancers Program at City of Hope Comprehensive Cancer Center in Duarte, California.
Dr. Rugo trained at the University of Pennsylvania School of Medicine and completed both her internal medicine residency and haematology/oncology fellowship at the University of California, San Francisco. She also undertook postdoctoral immunology research at Stanford University, reflecting her long-standing interest in cancer biology and immune-based treatment strategies. Before joining City of Hope in 2025, she spent approximately 35 years at UCSF, where she held senior academic and clinical leadership roles including Winterhof Family Distinguished Professor of Breast Cancer and Director of Breast Oncology and Clinical Trials Education. Her research has contributed to multiple treatment advances in breast cancer, including studies involving PARP inhibitors, CDK4/6 inhibitors, PI3K inhibitors, checkpoint inhibitors, and antibody-drug conjugates, as well as work that supported FDA approval of scalp cooling to reduce chemotherapy-related hair loss.
CancerFax can coordinate medical-report review and consultation support for international patients seeking an opinion from Dr. Rugo, subject to City of Hope's availability and case acceptance.
Why Consider Dr. Hope Rugo?
Dr. Rugo combines decades of clinical trial leadership with deep subspecialty expertise across all major breast cancer subtypes, making her a sought-after specialist for patients with complex or advanced breast cancer.
Areas of Specialisation
Comprehensive subspecialty expertise across early and advanced breast cancer, with a focus on novel systemic therapies and clinical trial innovation
Dr. Rugo's clinical and research practice spans all major breast cancer subtypes, with particular depth in metastatic disease, triple-negative breast cancer, hormone receptor-positive disease, and HER2-positive disease. She integrates biomarker-driven treatment selection, clinical trial access, and supportive care into a patient-centred approach.
Targeted Therapy & Immunotherapy
Advanced systemic treatment planning using molecularly guided and immune-based approaches for selected breast cancer subtypes.
- arrow_rightPARP inhibitor therapy for BRCA-associated breast cancer
- arrow_rightCDK4/6 inhibitor strategies for hormone receptor-positive advanced disease
- arrow_rightPI3K inhibitor combinations where applicable
- arrow_rightPD-1 and PD-L1 inhibitor treatment for eligible patients
- arrow_rightImmunotherapy combinations for triple-negative breast cancer
- arrow_rightResearch into improving immunotherapy response and understanding resistance mechanisms
- arrow_rightADC-based treatment planning for advanced and metastatic breast cancer
- arrow_rightIntegration of ADCs with other systemic therapy approaches
Metastatic & Advanced Breast Cancer
Comprehensive management of stage IV and recurrent breast cancer, with an emphasis on evidence-based systemic therapy, clinical trial access, and quality of life.
- arrow_rightChemotherapy, immunotherapy, and targeted approaches for TNBC
- arrow_rightCo-chair of the Triple Negative Working Group, Translational Breast Cancer Research Consortium
- arrow_rightEndocrine therapy combinations and sequencing strategies
- arrow_rightCDK4/6 and PI3K inhibitor regimens for advanced HR+/HER2- breast cancer
- arrow_rightHER2-directed targeted therapies and antibody-drug conjugates
- arrow_rightCombination regimens for HER2-positive early and metastatic disease
Supportive Care & Toxicity Management
Reducing the burden of treatment side effects and improving quality of life throughout cancer therapy.
- arrow_rightWork supporting FDA approval of scalp cooling to reduce chemotherapy-related hair loss
- arrow_rightSteroid mouthwash strategies to reduce targeted-therapy-related stomatitis
- arrow_rightSymptom management and patient-centred toxicity reduction integrated into treatment planning
Procedures & Clinical Approaches
Medical oncology services for breast cancer patients across all stages and subtypes
Dr. Rugo's clinical practice centres on systemic therapy for breast cancer, incorporating chemotherapy, targeted agents, immunotherapy, and antibody-drug conjugates. She also provides clinical trial-based treatment, second opinions, and supportive care planning.
Systemic Breast Cancer Treatment
Medical OncologyComprehensive medical oncology care for early, locally advanced, and metastatic breast cancer across all major subtypes.
Targeted & Immune-Based Therapy
Targeted TherapyBiomarker-driven and molecularly guided treatment planning using targeted agents and immunotherapy combinations.
Clinical Trial-Based Treatment
Complex DiseaseAccess to investigational therapies through clinical trials, including I-SPY2 neoadjuvant trials and other breast cancer research programmes.
Second Opinion Consultation
Second OpinionExpert review of diagnosis, pathology, imaging, and treatment plans for breast cancer patients seeking a specialist second opinion.
Supportive Care & Monitoring
MonitoringOngoing management of treatment-related side effects, liquid biopsy monitoring, and quality-of-life support throughout breast cancer therapy.
Research & Publications
More than 500 peer-reviewed publications and major clinical trial leadership in breast oncology
Dr. Rugo is among the most prolific and widely cited breast cancer researchers in the United States. Her work spans novel systemic therapies, resistance mechanisms, immunotherapy optimisation, and supportive care innovation, with contributions to multiple landmark breast cancer treatment advances.
A full publication list is available through PubMed, Google Scholar, and the Breast Cancer Research Foundation researcher profile for Dr. Hope S. Rugo.
Education & Training
Dr. Rugo completed her undergraduate training in Chemistry at Tufts University, her medical degree at the University of Pennsylvania, and her clinical specialty training entirely at UCSF — including internal medicine residency and haematology/oncology fellowship. She also pursued postdoctoral immunology research at Stanford University.
Clinical Experience
Dr. Rugo built one of the most distinguished careers in breast medical oncology over more than three decades at UCSF before joining City of Hope in 2025, where she now leads breast oncology and the Women's Cancers Program across a national cancer network.
Languages & International
Dr. Rugo consults in the following language. Additional languages spoken by Dr. Rugo are not confirmed in public sources.
CancerFax can coordinate professional medical interpreter support for international patients when required.
CancerFax can coordinate professional medical interpreter support for international patients consulting with Dr. Rugo.
How CancerFax Helps You Access Dr. Hope Rugo
CancerFax is a specialist cancer patient-navigation platform. We help international patients prepare structured medical summaries, assess treatment eligibility, and connect directly with Dr. Hope Rugo's team — with full coordination from initial inquiry to consultation.
Medical Report Review
Free review of your pathology results, imaging, molecular profiling, and treatment history — prepared as a structured clinical summary for Dr. Hope Rugo's team.
Treatment Eligibility Screening
CancerFax screens your case for eligibility for treatments and clinical programmes available through Dr. Hope Rugo before you travel, so you arrive with a clear pathway.
Case Submission
We coordinate direct case submission to Dr. Hope Rugo's department, including all documentation required for clinical review and appointment scheduling.
Appointment & Consultation Coordination
CancerFax manages appointment scheduling with Dr. Hope Rugo's team, confirming availability and aligning timelines with your travel plans.
Travel, Visa & Logistics Support
We prepare visa invitation letters, provide hospital-proximity accommodation guidance, and coordinate airport transfers for international patients.
Follow-Up & Continuity of Care
After your consultation or treatment, CancerFax facilitates communication between Dr. Hope Rugo's team and your home oncologist for seamless post-treatment follow-up.
Frequently Asked Questions About Dr. Hope Rugo
Dr. Hope Rugo specialises in breast cancer, including early-stage breast cancer, locally advanced breast cancer, metastatic breast cancer, triple-negative breast cancer, HER2-positive breast cancer, and hormone receptor-positive/HER2-negative breast cancer. She also leads City of Hope's Women's Cancers Program, which covers a broader range of women's cancer diagnoses.
Dr. Hope Rugo is currently at City of Hope Comprehensive Cancer Center in Duarte, California, where she serves as Division Chief of Breast Medical Oncology and Director of the Women's Cancers Program. She joined City of Hope in 2025 after approximately 35 years at the University of California, San Francisco (UCSF).
You can submit your medical reports through CancerFax. The CancerFax team will review your documents, prepare the case for submission, and coordinate the next steps with City of Hope, subject to the doctor's availability and case acceptance. This pathway is available for patients seeking a consultation or second opinion on a breast cancer diagnosis or treatment plan.
A second-opinion request can be submitted through CancerFax with the patient's pathology reports, imaging, treatment history, and relevant test results. Dr. Rugo's expertise in advanced systemic therapies, clinical trial options, and breast cancer subtypes makes her a valuable second-opinion specialist for patients with complex or metastatic disease. The final consultation format and availability depend on City of Hope's scheduling.
Dr. Rugo is recognised for her work with targeted therapies including PARP inhibitors, CDK4/6 inhibitors, PI3K inhibitors, and antibody-drug conjugates. She also has deep expertise in checkpoint inhibitor immunotherapy, particularly for triple-negative breast cancer, and has contributed to research on reducing treatment-related toxicities including scalp cooling and stomatitis management.
Yes. Dr. Rugo has an extensive history of clinical trial leadership. She chairs the I-SPY2 Safety Committee, which oversees toxicity and safety for novel breast cancer drug combinations in the I-SPY neoadjuvant trial network. She has also served on steering committees for trials contributing to approvals of several major breast cancer therapy classes and is a member of the Breast Committee of the Alliance for Clinical Trials in Oncology. Patients who may benefit from investigational therapies are encouraged to discuss clinical trial eligibility during consultation.
Dr. Rugo's current affiliation is with City of Hope Comprehensive Cancer Center in the United States. Specific international-patient services such as teleconsultation or multilingual coordination were not confirmed in public sources at the time of writing. CancerFax can assist with medical-report review and coordination of a consultation request, subject to institutional availability and case acceptance. International patients should confirm appointment pathways directly with City of Hope or through CancerFax.
Connect with Hope Rugo Today
Share your medical reports for a free preliminary review. Our patient coordinators will help you understand your options and arrange a direct consultation.
Medical Disclaimer: Information on this page is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making any medical decisions.